Axsome Therapeutics Inc will existing new facts on solriamfetol’s cognitive and wake-advertising and marketing outcomes at the American Academy of Neurology 2024 once-a-year meeting.
Solriamfetol (brand name Sunosi, Axsome) is permitted for sufferers with too much daytime sleepiness owing to narcolepsy and obstructive sleep apnea.
Details for the shows are as follows:
Title: Solriamfetol improves cognitive effectiveness in preclinical models of rest apnea and in a randomized placebo-controlled examine of sleep apnea participants (SHARP) P
Guide author: David Gozal, MD, MBA, Marie M. and Harry L. Smith Endowed Chair and the chairman of the division of boy or girl health and fitness at the University of Missouri
Session Title: P9: Snooze 2 Presentation day and time: Wednesday, April 17, from 8 am to 9 am MT
Software Quantity: P9.004
Title: Solriamfetol for too much sleepiness in narcolepsy and obstructive slumber apnea: effect dimensions and numbers desired to take care of or harm
Presentation date and time: Wednesday, April 17, from 11:45 am to 12:45 pm MT
Direct writer: Craig Chepke, MD, DFAPA, SUNY Upstate Health care University
Session name: P10: Slumber 3
Plan variety: P10.009
Title: SURWEY review of solriamfetol: initiation, titration, basic safety, efficacy, and follow-up practical experience for sufferers with OSA in Germany
Presentation date and time: Wednesday, April 17, from 8 am to 9 am MT
Lead writer: Yaroslav Wintertime, MD, University of Medication Mainz
Session name: P9: Rest 2
Software quantity: P9.010
Photo 7579430 © Donkeyru | Dreamstime.com
Leave a Reply